Index. Rheum Dis Clin N Am 32 (2006) Note: Page numbers of article titles are in boldface type.

Transcription

1 Rheum Dis Clin N Am 32 (2006) Index Note: Page numbers of article titles are in boldface type. A AACE (American Association of Clinical Endocrinologists), bone mineral density recommendations of, 683, 686 Adherence, to medications, barriers to, 726 definitions of, for osteoporosis, in asymptomatic diseases, 722 measurement of, 722 poor causes of, 726 consequences of, in chronic diseases, 722 in osteoporosis, reasons for, 727 strategies for improving, Age factors, in osteoporosis, 736 Alendronate compliance with, 724 duration of therapy with, efficacy of, osteoporosis, osteoporosis, 765 in combination therapy, 697 parathyroid hormone with, 709, 711 Alfacalcidol, Allele-sharing methods, in linkage analysis, ALOX15 gene, polymorphisms of, American Association of Clinical Endocrinologists (AACE), bone mineral density recommendations of, 683, 686 Ankylosing spondylitis, osteoporosis and fractures in, 642 Arthritis psoriatic, , 761 rheumatoid. See Rheumatoid arthritis. Association studies, of candidate genes, chloride channel 7, 673 collagen type I alpha I, core-binding factor A 1, estrogen receptor alpha, lipoprotein receptor related protein 5, osteoclast-specific proton pump, 673 transforming growth factor beta 1, 671 tumor necrosis factor receptor superfamily 1B, 673 vitamin D receptor, B Bisphosphonates, See also specific agents. compliance with, differences among, dosing intervals for, 728 duration of therapy with, efficacy of, for fracture prevention, osteoporosis, for Paget s disease, in combination therapy, 697 jaw osteonecrosis due to, 699 parathyroid hormone with, pharmacology of, Bone histomorphometry of, in osteoporosis, metabolism of, in glucocorticoidinduced osteoporosis, Bone mineral density, adherence with therapy and, animal studies of, fracture risk and, X/06/$ - see front matter Ó 2006 Elsevier Inc. All rights reserved. doi: /s x(06) rheumatic.theclinics.com

2 776 INDEX Bone (continued ) guidelines for measurement, in ankylosing spondylitis, in BFA1 gene polymorphisms, in CLCN7 gene mutations, 673 in COLIA1 gene polymorphisms, in ESR1 gene polymorphisms, in LRP5 gene polymorphisms, in osteoarthritis, in polymyalgia rheumatica, 647 in psoriatic arthritis, in rheumatoid arthritis, in systemic sclerosis, 646 in TRGb1 gene polymorphisms, 671 in VDR gene polymorphisms, linkage analysis of, 664 measurement of, remembering results of, 727 parathyroid hormone effects on, racial differences in, 622 TNFRSF1B gene polymorphisms, 673 versus fracture prediction, 626 C Calcaneal osteoporosis, in rheumatoid arthritis, 634 Calcidiol, Calcitonin, Calcitriol, Calcium supplementation, for osteoporosis, 741, 743 Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM), adherence issues in, Candidate genes, association studies of, CBFA1 gene polymorphisms, CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity), adherence issues in, Cholecalciferol, CLCN7 gene mutations, 673 Clodronate, for osteoporosis efficacy of, , 745 inflammation-induced, 766 COLIA1 gene polymorphisms, Collagen type I alpha I, defects of, Compliance, to medication regimen, definition of, Core-binding factor A 1, defects of, Corticosteroids. See Glucocorticoidinduced Cortisol osteoporosis due to. See Glucocorticoid-induced physiology of, Cytokines, in inflammation-induced osteoporosis, D Denosumab, for osteoporosis dosing of, 728 inflammation-induced, 765 Dihydrotachysterol, for glucocorticoidinduced Disease-modifiying drugs, osteoporosis due to, 636 E Economic issues, in osteoporosis, Erosions, in rheumatoid arthritis, 760 ESR1 gene polymorphisms, Estrogen(s) bisphosphonates with, 697 deficiency of, in osteoporosis, parathyroid hormone with, Estrogen receptor alpha, defects of, Etidronate, for osteoporosis efficacy of, 694, inflammation-induced, 766

3 European Prospective Osteoporosis Study, 621 European Vertebral Osteoporosis Study, 623 F Falls, fractures in, 624, 626, 637 Fluoride, osteoporosis, 748 Forearm fractures epidemiology of, in falls, 626 morbidity in, 621 mortality in, subsequent fracture prediction from, Forearm osteoporosis, in rheumatoid arthritis, 634 Fracture(s). See also specific locations, eg, Hip; Wrist. bone mineral density and, 626 clustering of, economic cost of, epidemiology of, falls and, 626 future projections for, health impact of, in ankylosing spondylitis, in osteoarthritis, in poor adherence to treatment, in rheumatoid arthritis, morbidity in, mortality due to, risk factors for, preventive treatment based on, Fracture Intervention Trial, 692 G Gender differences, in glucocorticoidinduced osteoporosis, 736 Genetic factors, in osteoporosis, animal studies of, association studies of candidate genes in, linkage analysis of, Genome-wide scans, in linkage analysis, 664 Glucocorticoid-induced osteoporosis, INDEX 777 epidemiology of, 733 evaluation of, 741 fracture risk in, 733 in rheumatoid arthritis, parathyroid hormone for, pathophysiology of, treatment of, , 724, H Hip/femoral fractures epidemiology of, , in falls, 626 in osteoarthritis, 649 in rheumatoid arthritis, morbidity in, mortality in, prevention of, bisphosphonates for, 693 Hip/femoral osteoporosis genome-wide scans of, 664 in ankylosing spondylitis, 643 in osteoarthritis, 649 in psoriatic arthritis, 647 in rheumatoid arthritis, Hopkins Lupus Cohort, 640 Humeral fractures, epidemiology of, Hydrocortisone, osteoporosis due to. See Glucocorticoid-induced Hypercalcemia, due to parathyroid hormone, Hyperparathyroidism, in osteoporosis, 738 I Ibandronate dosing of, 728 efficacy of, osteoporosis, 765 Immunoreceptor tyrosine-based activation, in inflammation-induced osteoporosis, 763 Inflammation-induced osteoporosis, osteoclastogenesis in, , 765 pathophysiology of, T cells in, 762

4 778 INDEX Inflammation-induced (continued) treatment of, bisphosphonates in, osteoclastogenesis inhibitors in, 765 parathyroid hormone in, tumor necrosis factor a inhibitors in, Interferon(s), in inflammation-induced osteoporosis, 762 Interleukin(s), in inflammation-induced osteoporosis, International Osteoporosis Foundation, on fracture prevention, 687 International Society for Clinical Densitometry (ISCD), bone mineral density recommendations of, 681, J Jaw, osteonecrosis of, due to bisphosphonates, 699 L Linkage analysis, of osteoporosis susceptibility genes, Lipoprotein receptor related protein 5, defects of, Lodscores, in linkage analysis, LRP5 gene polymorphisms, M Methotrexate osteoporosis, 764 for rheumatoid arthritis, osteoporosis due to, 634 Metoodronate, efficacy of, 694 N NAMS (North American Menopause Society), bone mineral density recommendations of, , 686 Nandrolone, National Osteoporosis Foundation (NOF), bone mineral density recommendations of, 683, 686 NFATc1 (nuclear factor of activated T cells c1), in inflammation-induced osteoporosis, 763 NOF (National Osteoporosis Foundation), bone mineral density recommendations of, 683, 686 Nonadherence, to medications causes of, 726 consequences of, in asymptomatic diseases, 722 in chronic diseases, 722 in osteoporosis, North American Menopause Society (NAMS), bone mineral density recommendations of, , 686 Nuclear factor of activated T cells c1 (NFATc1), in inflammation-induced osteoporosis, 763 O Osteoarthritis, osteoporosis in, Osteoblast(s) in osteoporosis, 739 stimulation of, for inflammationinduced osteoporosis, Osteoclast(s), in osteoporosis, 739 Osteoclastogenesis, , 765 Osteoclast-specific proton pump, defects of, 673 Osteonecrosis, of jaw, due to bisphosphonates, 699 Osteopenia, juxta-articular, in rheumatoid arthritis, 760 Osteoporosis bone mineral density measurement in, definition of, 617, 681 epidemiology of, in ankylosing spondylitis, in osteoarthritis, in polymyalgia rheumatica, 647 in psoriatic arthritis, in rheumatic diseases, in rheumatoid arthritis, in systemic sclerosis, fractures in. See Fracture(s). genetics of,

5 . See Glucocorticoid-induced in ankylosing spondylitis, in osteoarthritis, in polymyalgia rheumatica, 647 in psoriatic arthritis, , 761 in rheumatoid arthritis, , in systemic sclerosis, inflammation-induced, pathophysiology of, inflammation-induced, secondary diseases associated with, 684 drugs associated with, 685 treatment of adherence to, based on bone mineral density results, bisphosphonates for. See Bisphosphonates., inflammation-induced, parathyroid hormone for. See Parathyroid hormone. Osteoporosis Risk Assessment Index, 685 Osteoporosis Self-Assessment Tool (OST), Osteoprotegerin system, in inflammationinduced osteoporosis, 761, 765 P Paget s disease, Pamidronate, osteoporosis, 745 Parathyroid hormone, for osteoporosis, bisphosphonates with, 697 clinical trials of, contraindications for, 716, , 748 guidelines for, 716 in combination therapy, in cyclic therapy, 711 in men, 708 in monotherapy, in sequential treatment, indications for, 716 inflammation-induced, physiology of, INDEX postmenopausal, safety of, Pedigrees, linkage analysis of, in osteoporosis, Pelvic fractures, , 636 Persistence, in medication regimen, definition of, 722 Polymyalgia rheumatica, osteoporosis in, 647 Prasterone, Prednisolone, osteoporosis due to. See Glucocorticoid-induced Prednisone, osteoporosis due to. See Glucocorticoid-induced Psoriatic arthritis, osteoporosis in, , Q Quantitative trait loci, in linkage analysis, 661, R Racial factors, in fracture epidemiology, 622 Raloxifene, parathyroid hormone with, 712 Receptor activator of nuclear factor kappa B ligand (RANKL) in osteoporosis, in inflammation-induced osteoporosis, Rheumatoid arthritis bone loss in, types of, 760 fractures in, osteoporosis in, epidemiology of, pathophysiology of, treatment of, Risedronate compliance with, duration of therapy with, efficacy of, osteoporosis, osteoporosis, 765 RUNX2 (CBFA1) gene polymorphisms,

6 780 INDEX S Scleroderma, osteoporosis in, Sib-pairs, in linkage analysis, 661 Simple Calculated Osteoporosis Risk Equation (SCORE), Spinal fractures. See Vertebral fractures. Spinal See Vertebral Spondyloarthropathies, osteoporosis and fractures in, 642 Study of Osteoporotic Fractures, 625 Systemic lupus erythematosus, osteoporosis in epidemiology of, fractures in, Systemic sclerosis, osteoporosis in, T T cells, in inflammation-induced osteoporosis, 762 Teriparatide (rhpth [1-34]), for osteoporosis clinical trials of, , 748 guidelines for, 716 in combination therapy, 709, in monotherapy, safety of, Testosterone deficiency of, in osteoporosis, 740 Tibial fractures, Tibolone, 744 TNFRSF1B gene polymorphisms, 673 Transforming growth factor beta 1, defects of, 671 TRGb1 gene polymorphisms, 671 Tumor necrosis factor a, in inflammation-induced osteoporosis, Tumor necrosis factor receptor superfamily 1B, defects of, 673 U Ultrasonography, in osteoporosis, 664 V Variance component linkage analysis, VDR gene polymorphisms, Vertebral fractures epidemiology of, , in ankylosing spondylitis, in osteoporosis, 736 in osteoarthritis, 650 in rheumatoid arthritis, morbidity in, mortality in, prevention of, , risk factors for, subsequent fracture prediction from, 625 Vertebral osteoporosis in ankylosing spondylitis, 643 in osteoarthritis, 649 in psoriatic arthritis, 647 in rheumatoid arthritis, Vitamin D receptor, defects of, Vitamin D supplementation, for osteoporosis, 741, 743 W Women s Health Initiative, , Wrist fractures, epidemiology of, 624 Z Zoledronate dosing of, 728 efficacy of, osteoporosis,